|
1
|
Shaw JE, Sicree RA and Zimmet PZ: Global
estimates of the prevalence of diabetes for 2010 and 2030. Diabetes
Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bell DS: Heart failure: The frequent,
forgotten, and often fatal complication of diabetes. Diabetes Care.
26:2433–2441. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fang ZY, Prins JB and Marwick TH: Diabetic
cardiomyopathy: Evidence, mechanisms, and therapeutic implications.
Endocr Rev. 25:543–567. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Westermann D, Walther T, Savvatis K,
Escher F, Sobirey M, Riad A, Bader M, Schultheiss HP and Tschöpe C:
Gene deletion of the kinin receptor B1 attenuates cardiac
inflammation and fibrosis during the development of experimental
diabetic cardiomyopathy. Diabetes. 58:1373–1381. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falcão-Pires I and Leite-Moreira AF:
Diabetic cardiomyopathy: Understanding the molecular and cellular
basis to progress in diagnosis and treatment. Heart Fail Rev.
17:325–344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aksakal E, Akaras N, Kurt M, Tanboga IH,
Halici Z, Odabasoglu F, Bakirci EM and Unal B: The role of
oxidative stress in diabetic cardiomyopathy: An experimental study.
Eur Rev Med Pharmacol Sci. 15:1241–1246. 2011.PubMed/NCBI
|
|
7
|
Halliwell B: Biochemistry of oxidative
stress. Biochem Soc Trans. 35:1147–1150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matés JM and Sánchez-Jiménez F:
Antioxidant enzymes and their implications in pathophysiologic
processes. Front Biosci. 4:D339–D345. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mellor H and Parker P: The extended
protein kinase C superfamily. Biochem J. 332:281–292. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gurusamy N, Watanabe K, Ma M, Zhang S,
Muslin AJ, Kodama M and Aizawa Y: Inactivation of 14-3-3 protein
exacerbates cardiac hypertrophy and fibrosis through enhanced
expression of protein kinase C beta 2 in experimental diabetes.
Biol Pharm Bull. 28:957–962. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Way KJ, Isshiki K, Suzuma K, Yokota T,
Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ,
Wakasaki H and King GL: Expression of connective tissue growth
factor is increased in injured myocardium associated with protein
kinase C beta2 activation and diabetes. Diabetes. 51:2709–2718.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Migliaccio E, Giorgio M, Mele S, Pelicci
G, Reboldi P, Pandolfi PP, Lanfrancone L and Pelicci PG: The p66shc
adaptor protein controls oxidative stress response and life span in
mammals. Nature. 402:309–313. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nemoto S and Finkel T: Redox regulation of
forkhead proteins through a p66shc-dependent signaling pathway.
Science. 295:2450–2452. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pinton P, Rimessi A, Marchi S, Orsini F,
Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F,
Wieckowski MR, et al: Protein kinase C beta and prolyl isomerase 1
regulate mitochondrial effects of the life-span determinant p66Shc.
Science. 315:659–663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paneni F, Mocharla P, Akhmedov A,
Costantino S, Osto E, Volpe M, Lüscher TF and Cosentino F: Gene
silencing of the mitochondrial adaptor p66shc suppresses vascular
hyperglycemic memory in diabetes. Circ Res. 111:278–289. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arab HH and El-Sawalhi MM: Carvedilol
alleviates adjuvant-induced arthritis and subcutaneous air pouch
edema: Modulation of oxidative stress and inflammatory mediators.
Toxicol Appl Pharmacol. 268:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yasar A, Erdemir F, Parlaktas BS, Atilgan
D, Koseoglu RD, Saylan O and Firat F: The effect of carvedilol on
serum and tissue oxidative stress parameters in partial ureteral
obstruction induced rat model. Kaohsiung J Med Sci. 29:19–25. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feuerstein GZ, Poste G and Ruffolo RR Jr:
Carvedilol update III: Rationale for and use in congestive heart
failure. Drugs Today. 31:307–326. 1995. View Article : Google Scholar
|
|
19
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the care and use of laboratory animals.
(Eighth). Publication no. 85-23(rev). 327:963–965. 1996.
|
|
20
|
Maeda H, Nagai H, Takemura G,
Shintani-Ishida K, Komatsu M, Ogura S, Aki T, Shirai M, Kuwahira I
and Yoshida K: Intermittent-hypoxia induced autophagy attenuates
contractile dysfunction and myocardial injury in rat heart. Biochim
Biophys Acta. 1832:1159–1166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frustaci A, Kajstura J, Chimenti C,
Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B and Anversa P:
Myocardial cell death in human diabetes. Circ Res. 87:1123–1132.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Li B, Wang W, Zhang C, Zhang M,
Zhang Y, Xia Y, Dong Z, Guo Y and An F: Effects of HMG-CoA
reductase inhibitor on experimental autoimmune myocarditis.
Cardiovasc Drugs Ther. 26:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lei S, Li H, Xu J, Liu Y, Gao X, Wang J,
Ng KF, Lau WB, Ma XL, Rodrigues B, et al: Hyperglycemia-induced
protein kinase C β2 activation induces diastolic cardiac
dysfunction in diabetic rats by impairing caveolin-3 expression and
Akt/eNOS signaling. Diabetes. 62:2318–2328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang H, Shan J, Pan XH, Wang HP and Qian
LB: Carvedilol protected diabetic rat hearts via reducing oxidative
stress. J Zhejiang Univ Sci B. 7:725–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olsen SL, Gilbert EM, Renlund DG, Taylor
DO, Yanowitz FD and Bristow MR: Carvedilol improves left
ventricular function and symptoms in chronic heart failure: A
double-blind randomized study. J Am Coll Cardiol. 25:1225–1231.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Packer M, Bristow MR, Cohn JN, Colucci WS,
Fowler MB, Gilbert EM and Shusterman NH: The effect of carvedilol
on morbidity and mortality in patients with chronic heart failure.
N Engl J Med. 334:1349–1355. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tarquini R, Lazzeri C, Pala L, Rotella CM
and Gensini GF: The diabetic cardiomyopathy. Acta Diabetol.
48:173–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou H, Li YJ, Wang M, Zhang LH, Guo BY,
Zhao ZS, Meng FL, Deng YG and Wang RY: Involvement of RhoA/ROCK in
myocardial fibrosis in a rat model of type 2 diabetes. Acta
Pharmacol Sin. 32:999–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morsy MA, Ibrahim SA, Amin EF, Kamel MY,
Abdelwahab SA and Hassan MK: Carvedilol ameliorates early diabetic
nephropathy in streptozotocin-induced diabetic rats. Biomed Res
Int. 2014:1052142014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rajesh M, Mukhopadhyay P, Bátkai S, Patel
V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B,
Becker L, et al: Cannabidiol attenuates cardiac dysfunction,
oxidative stress, fibrosis, and inflammatory and cell death
signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol.
56:2115–2125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Z, Wang G, Zhai X, Hu Y, Gao D, Ma L,
Yao J and Tian X: Selective inhibition of protein kinase C β2
attenuates the adaptor P66Shc-mediated intestinal
ischemia-reperfusion injury. Cell Death Dis. 5:e11642014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clarke M and Dodson PM: PKC inhibition and
diabetic microvascular complications. Best Pract Res Clin
Endocrinol Metab. 21:573–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simpson PC: Beta-protein kinase C and
hypertrophic signaling in human heart failure. Circulation.
99:334–337. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Connelly KA, Kelly DJ, Zhang Y, Prior DL,
Advani A, Cox AJ, Thai K, Krum H and Gilbert RE: Inhibition of
protein kinase C-beta by ruboxistaurin preserves cardiac function
and reduces extracellular matrix production in diabetic
cardiomyopathy. Circ Heart Fail. 2:129–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Devereux RB, Roman MJ, Paranicas M,
O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER and
Howard BV: Impact of diabetes on cardiac structure and function the
strong heart study. Circulation. 101:2271–2276. 2000. View Article : Google Scholar : PubMed/NCBI
|
